How to use luspatercept and erythropoiesis‐stimulating agents in low‐risk myelodysplastic syndrome
British Journal of Haematology, Volume 207, Issue 1, Page 15-26, July 2025.Summary Anaemia is the most common cytopenia in myelodysplastic syndrome (MDS), significantly impacting quality of life and morbidity. Erythropoiesis‐stimulating agents (ESAs) are the first‐line treatment for anaemia in lower risk (LR)‐MDS. The European Medicines Agency (EMA) approved epoetin alpha for LR‐MDS‐related anaemia in 2017, based on evidence ...
Valeria Santini, Angela Consagra
wiley +1 more source
Randomized Trial of Pegmolesatide for the Treatment of Anemia in Patients With Nondialysis CKD
Kidney International ReportsIntroduction: Pegmolesatide has been recently approved for treating anemia in chronic kidney disease (CKD) patients in China. We presented the results of the pivotal study conducted in patients with nondialysis-dependent (NDD)-CKD with anemia.
Jianteng Xie +15 more
doaj +1 more source
Reviewing the Drivers and Challenges in RFID Implementation in the Pharmaceutical Supply Chain [PDF]
, 2009 Counterfeiting is a global phenomenon that poses a serious financial threat to the pharmaceutical industry and more importantly jeopardizes public safety and security.
Li, Suhong +2 more
core +2 more sources
Nephrology, Volume 30, Issue 7, July 2025.ABSTRACT Parvovirus B19 infection can rarely manifest with pure red cell aplasia in immunocompromised hosts. This case details a 48‐year‐old male, 11 years post kidney‐pancreas transplant who was admitted with a chronic normocytic anaemia (haemoglobin 72 g/L) after being admitted four months prior with a bleeding peptic ulcer, requiring eight units of ...
Oscar Perry +5 more
wiley +1 more source
BMC Nephrology, 2012 Background Peginesatide is a peptide-based erythropoiesis-stimulating agent that was designed and engineered to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis. The primary objective of this phase 2 dose-finding study
Besarab Anatole +10 more
doaj +1 more source
The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer-treatment induced anaemia (including review of TA142): a systematic review and economic model [PDF]
, 2016 Background: Anaemia is a common side-effect of cancer treatments and can lead to a reduction in quality of life. Erythropoiesis-stimulating agents (ESAs) are licensed for use in conjunction with red blood cell transfusions (RBCTs) to improve cancer ...
Briscoe, Simon +12 more
core
Effect of angiotensin-converting enzyme gene insertion/deletion polymorphism and angiotensin-converting enzyme inhibition on erythropoiesis in patients on haemodialysis. [PDF]
, 2018 BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEis) improve survival; however, their effect on erythropoiesis remains a matter of debate in this population.
Ambrus, Csaba +5 more
core +1 more source
Use of erythropoiesis stimulating agents [PDF]
, 2014 UNIFESP Hospital São Paulo Setor de HemodiáliseHospital Beneficência PortuguesaUFJF Serviço de Nefrologiacentro de pesquisa IMEPENUNIFESP, Hospital São Paulo Setor de ...
Abreu, Patricia Ferreira +2 more
core +3 more sources
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial [PDF]
, 2010 Peginterferon plus ribavirin achieves sustained virological response (SVR) in fewer than half of patients with genotype 1 chronic hepatitis C virus infection treated for 48 weeks.
Albrecht, J. +19 more
core +1 more source